Analyst Price Target is $36.00
▲ +398.59% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aptevo Therapeutics in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 398.59% upside from the last price of $7.22.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Aptevo Therapeutics. This Buy consensus rating has held steady for over two years.
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.